NEWS

NEWS , Press release 2025.10.28  Rebirthel and C4U Entered into a Memorandum of Understanding Aiming for the Collaborative Research

Rebirthel Co., Ltd. and C4U Corporation (“C4U”) are pleased to announce that we have entered in...

READ MORE
Column 2025.10.10 Special Message “On the occasion of Prof. Shimon Sakaguchi’s winning the Nobel Prize in Physiology or Medicine”

Congratulations to Professor Shimon Sakaguchi and his wife, Mrs. Noriko Sakaguchi, on winning t...

READ MORE
NEWS , Press release 2025.10.6  Rebirthel concludes Exclusive License Agreement for Patent on T Cell medicine for COVID-19 

Rebirthel concludes Exclusive License Agreement for Patent on T Cell medicine for COVID-19 with...

READ MORE
NEWS , Press release 2025.9.10 Strategic Alliance Agreement with Eutilex (Korea) on the Development of Next-Generation Allogeneic CAR-T Therapies Derived from iPS Cells

Rebirthel and Eutilex announce that they have entered into a contract on entered into a Strateg...

READ MORE
NEWS 2024.12.14 Article on Rebirthel‘s exhibiting at Expo 2025 Osaka, Kansai on Yomiuri Shimbun (Japanese newspaper)

Rebirthel was featured on Yomiuri Shimbun on December 14th, 2024. The article is titled “Review...

READ MORE
NEWS 2024.2.16 Rebirthel was featured on Nikkan Kogyo Shimbun (Japanese newspaper)

Following the appearance in the article on January 10th, Rebirthel’s activity was introduced in...

READ MORE
NEWS 2024.1.10 Rebirthel was featured on Nikkan Kogyo Shimbun (Japanese newspaper)

In Nikkan Kogyou Shimbun on January 10 th , 2024 (Page 13), the interview article of ourCOE, Ma...

READ MORE
NEWS , Press release 2023.6.6 Rebirthel signs Strategic Alliance Agreement with H.U. Group Research Institute G.K. to develop next-generation immune cell therapy based on Rebirthel’s patented technology to produce universal allogeneic T cells

Rebirthel Co., Ltd. (Rebirthel) announced that it has entered into a strategic alliance agreeme...

READ MORE
NEWS 2023.5.29 Rebirthel signs collaborative research agreement  for the development of automated cell mass culture technology  to spread allogenic T cell therapy

Rebirthel Co., Ltd. (Rebirthel) announced that it entered into a collaboration research agreeme...

READ MORE
NEWS , Press release 2023.4.24 Alliance between Noile-Immune Biotech, Inc. and Rebirthel Co., Ltd. on PRIME allogeneic CAR-T Cell Therapy using Immune Cells induced from Pluripotent Stem Cells

Rebirthel and Noile-Immune Biotech announce that they have entered into a contract on collabora...

READ MORE